Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.
Brownlow
N
N
Mol
C
C
Hayford
C
C
Ghaem-Maghami
S
S
Dibb
N J
NJ
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001201:Ascites / Q000209:etiology / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D000069439:Dasatinib; D018450:Disease Progression; D005260:Female; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000502:physiology; D008958:Models, Molecular; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D009389:Neovascularization, Pathologic / Q000473:pathology; D010010:Osteoclasts / Q000187:drug effects*; D010051:Ovarian Neoplasms / Q000097:blood / Q000150:complications / Q000473:pathology; D017354:Point Mutation; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D053245:RANK Ligand / Q000502:physiology; D051381:Rats; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors; D013844:Thiazoles / Q000494:pharmacology*
D000970:Antineoplastic Agents; D007377:Interleukin-3; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D053245:RANK Ligand; D011993:Recombinant Fusion Proteins; C505688:TNFSF11 protein, human; D013844:Thiazoles; D016173:Macrophage Colony-Stimulating Factor; D016186:Receptor, Macrophage Colony-Stimulating Factor; D000069439:Dasatinib